CorrespondenceCardiac contractility modulation signals improve exercise intolerance and maladaptive regulation of cardiac key proteins for systolic and diastolic function in HFpEF
Section snippets
Conflict of interest
C. Tschöpe, A. Remppis and M. Roser have received lecture honoraria from IMPULSE Dynamics. D. Gutterman is a consultant to IMPULSE Dynamics.
References (15)
- et al.
Efficacy and survival in patients with cardiac contractility modulation: long-term single center experience in 81 patients
Int. J. Cardiol.
(2015) - et al.
Impact of cardiac contractility modulation on left ventricular global and regional function and remodeling
JACC Cardiovasc. Imaging.
(2009) - et al.
Cardiac contractility modulation electrical signals improve myocardial gene expression in patients with heart failure
J. Am. Coll. Cardiol.
(2008) - et al.
Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction
J. Am. Coll. Cardiol.
(2011) - et al.
A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation
J. Am. Coll. Cardiol.
(2013) - et al.
New therapy concepts for heart failure with preserved ejection fraction
Herz
(2015) - et al.
Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM
Eur. J. Heart Fail.
(2007)
There are more references available in the full text version of this article.
Cited by (42)
Role of Cardiac Contractility Modulation in Heart Failure With a Higher Ejection Fraction
2022, Journal of Cardiac FailureCitation Excerpt :Cardiac fibrosis and myofilament hypophosphorylation are major factors leading to diastolic dysfunction in HFpEF.3,23,24 Tschope et al. performed a prospective analysis of 2 patients with HFpEF treated with CCM therapy with serial histological analysis of endomyocardial tissue at 30 minutes and 3 months to determine changes in contractile protein function and gene expression of cardiac myocytes.25 The findings were consistent with the biomolecular effects described with CCM therapy in HFrEF.
Future Therapies in HFpEF
2020, Diastology: Clinical Approach to Heart Failure with Preserved Ejection FractionNovel treatments for diastolic heart failure
2020, Emerging Technologies for Heart Diseases: Volume 1: Treatments for Heart Failure and Valvular DisordersDevice therapy for patients with atrial fibrillation and heart failure with preserved ejection fraction
2024, Heart Failure Reviews
Copyright © 2015 Published by Elsevier Ireland Ltd.